About
Triplet State Technology LLC is a Washington State licensed LLC. The company’s primary office is at 49 View Ridge Lane, Longview, WA 98632. The company maintains a research office in Los Angeles, CA near the UCLA campus. Triplet State Technology LLC was formed to research and engineer applications of patents solely owned by Dr. Robert Sandstrom, company founder. The patents address methods for modifying the reaction dynamics of free radicals in tumor tissue. The clinical efficacy of radiation therapy is the direct result of radiation-induced free radicals. Free radicals generated in the process of radiation therapy are generally short-lived and their half-life largely determined by recombination events. Radiation sources may include external beam, implant, directed nanoparticle, and gamma knife techniques. The current Triplet State device is designed to work specifically with commonly employed linear accelerators. Conformational radiation methods localize the radiation to specific anatomic sites. The Sandstrom method has the advantage of contouring the magnetic field to the desired anatomic site. The Sandstrom method predicates a quantum effect which results from precession of free radicals in a selective structured magnetic field. Precession in the magnetic field limits recombination and increases the non recombinant free radical fraction which locally acts to kill tumor cells.
The UCLA Department of Radiation Oncology headed by Professor Michael Steinberg MD and specifically a scientific team which includes Dan Low PhD, William McBride PhD and Kei Iwamoto PhD entered into collaboration with Triplet State Technology LLC and Dr. Sandstrom to investigate the effect of a structured magnetic field of determinate field strength on tumor cell cultures and implanted tumors in mice.
A series of experimental efforts demonstrated the effect in human glioblastoma cell cultures and in Lewis Lung carcinoma cell cultures. Lewis lung carcinoma implants in syngeneic C57BL/6 mice demonstrated improved response to radiation therapy when the structured magnetic field was added to the treatment protocol. A level of cell growth inhibition in animal studies versus radiation alone suggested a benefit of 38%, which translated into higher tumor cell kill when the magnetic field was included.
In the course of developing and designing the experimental protocols, Triplet State Technologies partnered with RadiaBeam Technologies in Santa Monica to design and build a proprietary device to expose cell cultures and mice with a magnetic field of specific field strength and geometry. Triplet State and the UCLA research team have demonstrated that there is no demonstrable histologic tissue or hematologic injury in mice ascribable to the magnetic field in treated or control animals. RadiaBeam has been contracted to develop a prototype device for human trials.
RadiaBeam has designed, built, tested and delivered the Magnetic Coil Subset (MCS) device to HDA Technology for final assembly. Testing at Intertek, Inc. in Irvine, CA is scheduled for September and October 2022.